

Small Molecule Innovation

PharmaLex is your one stop source to instantly accelerate the development of innovative small molecules from R&D to market.



How are we different?

Only PharmaLex are a one stop source for innovative small molecule development for biotechs, small / medium as well as large pharma, when you need:

- ▶ Global presence with local reach.
- ▶ Operational excellence and rapid scale up.
- ▶ Ideal when you need a partner who is exceptional in biopharma and small molecule innovation together.
- ▶ Instant development capacity. With one strategic program lead and expertise available overnight.



There are over **176** monovalent degrader assets in development



Small molecules make up **90%** of pharmaceutical drugs (ex. insulin, aspirin, antihistamines)

Anti-Infectious Diseases

Inflammation

Oncology

Orphan Diseases

CNS

PSY



A total of **51 antibiotics** (including combinations) and **11 biologicals** were in the clinical pipeline to target priority pathogens, *M. tuberculosis* & *C. difficile*